Compare US Global Jets ETF (JETS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Novartis AG — how do they compare? US Global Jets ETF trades at $27.47 (market cap $878.48M), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 305.7× US Global Jets ETF's market cap, and Novartis AG pays a 3.31% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and Novartis AG for 82 Days on average.
| JETS | NVS | |
|---|---|---|
Market Cap | $878.48M | $268.57B |
Volume | 4,465,925 | 1,532,573 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $168.62 |
52-Week Low | $23.64 | $121.80 |
Typical Hold Time | 26 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS ETF trades at $27.29, down 1.37% amid bearish technical signals with 17 sell indicators versus 4 buy signals. The airline-focused ETF faces headwinds from rising fuel costs and geopolitical tensions, while technical analysis shows strong resistance at $28 and support at $27. Recent news highlights underperformance compared to defense-focused aerospace ETFs and pressure from Middle East conflicts driving up airline operating expenses.
The outlook remains challenging with fuel cost volatility and competitive pressure from alternative aerospace investments. While travel demand provides some support, the ETF's concentration on airline operators exposes investors to cyclical industry risks and margin compression from elevated fuel expenses. Near-term performance depends on fuel price stabilization and geopolitical developments.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
